A study testing whether an investigational anti-nausea medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

Recruiting now. Registry record last updated April 20, 2026.

Who can join: Adults 18 to 65, have nausea and vomiting, BMI 25+.
What you take: Tradipitant, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The study runs about 9 months.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor Vanda PharmaceuticalsDrug TradipitantClass OtherSites 10 USEnrollment target 280

What this study is for

Primary condition: Nausea and Vomiting. Also studied in: Obesity.

Full scientific study title: A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use.

Who can join

Age18 to 65SexAnyBMI25 to 40

Adults 18 to 65, have nausea and vomiting, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Body Mass Index ≥ 25 and \< 40 kg/m\^2
No serious medical problems or chronic diseases, specifically no type I or type II diabetes

Key exclusion criteria

Another disorder that contributes to gastrointestinal symptoms
History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
Exposure to any investigational medication within the past 60 days

Where this trial is enrolling

This trial has 10 sites across 6 states. Contact a site coordinator directly to start screening.

Find a site near you

California3 sites

Vanda Investigational Site
Los Angeles, California
Vanda Pharmaceuticals202-734-3400
Vanda Investigational Site
San Diego, California
Vanda Pharmaceuticals202-734-3400
Vanda Investigational Site
San Jose, California
Vanda Pharmaceuticals(202) 734-3400

Florida1 site

Vanda Investigational Site
Tampa, Florida
Vanda Pharmaceuticals(202) 734-3400

New Jersey1 site

Vanda Investigational Site
Hamilton, New Jersey
Vanda Pharmaceuticals(202) 734-3400

New York2 sites

Vanda Investigational Site
New York, New York
Vanda Pharmaceuticals202-734-3400
Vanda Investigational Site
Syosset, New York
Vanda Pharmaceuticals(202) 734-3400

Texas2 sites

Vanda Investigational Site
Plano, Texas
Vanda Pharmaceuticals(202) 734-3400
Vanda Investigational Site
San Antonio, Texas
Vanda Pharmaceuticals(202) 734-3400

Virginia1 site

Vanda Investigational Site
Burke, Virginia
Vanda Pharmaceuticals(202) 734-3400

Follow this trial

We email you if NCT07446439 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: March 27, 2026. Expected completion: December 1, 2026. Last updated on ClinicalTrials.gov: April 20, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.